U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10ClN3O
Molecular Weight 199.638
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LAZABEMIDE

SMILES

NCCNC(=O)C1=NC=C(Cl)C=C1

InChI

InChIKey=JZXRLKWWVNUZRB-UHFFFAOYSA-N
InChI=1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)

HIDE SMILES / InChI

Molecular Formula C8H10ClN3O
Molecular Weight 199.638
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12359039 | https://www.thepharmaletter.com/article/blow-for-roche-as-phase-iii-tempium-trials-are-discontinued

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under clinical development against Parkinson's disease, Alzheimer's disease and as an aid to smoking cessation. The development of the drug was discontinued due to liver toxicity.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.091 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
1993 Oct
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
1994 Sep
Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.
1996 Feb
Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.
1997 Mar
Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
2000 Sep 1
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex.
2003 Jul 11
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
2004 Sep
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
2011 Dec 8
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
2011 Jan 25
Patents

Patents

Sample Use Guides

In clinical trial against Parkinson's disease, lazabemide was administered orally at doses 25-200 mg/day
Route of Administration: Oral
Lazabemide inhibited recombinant human MAO-B with IC50 of 0.091 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:50:48 UTC 2023
Edited
by admin
on Sat Dec 16 16:50:48 UTC 2023
Record UNII
420HD787N9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LAZABEMIDE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
2-PYRIDINECARBOXAMIDE, N-(2-AMINOETHYL)-5-CHLORO-
Systematic Name English
LAZABEMIDE [MART.]
Common Name English
lazabemide [INN]
Common Name English
LAZABEMIDE [MI]
Common Name English
RO 19-6327/000
Code English
N-(2-Aminoethyl)-5-chloropicolinamide
Systematic Name English
RO-19-6327/000
Code English
Lazabemide [WHO-DD]
Common Name English
RO-196327
Code English
LAZABEMIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C667
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
Code System Code Type Description
EVMPD
SUB08418MIG
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
WIKIPEDIA
Lazabemide
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
ChEMBL
CHEMBL279390
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
USAN
EE-63
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID2048294
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
NCI_THESAURUS
C80964
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
SMS_ID
100000082563
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
INN
6874
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
CAS
103878-84-8
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
PUBCHEM
71307
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
MESH
C059303
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
FDA UNII
420HD787N9
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY
MERCK INDEX
m6719
Created by admin on Sat Dec 16 16:50:49 UTC 2023 , Edited by admin on Sat Dec 16 16:50:49 UTC 2023
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY